Vertex will partner with Kymera Therapeutics in a four-year development deal that hands the small biotech $70 million in cash and equity investment. All told, the collaboration could be worth more than $1 billion for Kymera, which is one of several biotechs exploring whether a new type of small molecule drug can degrade disease-causing proteins in ways current technologies like antibodies cannot. With its deal, Vertex joins larger biopharma companies like Roche, Biogen and Pfizer in betting on what’s termed targeted protein degradation, a field Kymera shares with C4 Therapeutics and Arvinas. Learn More